China Shineway Pharmaceutical Group Limited (02877.HK)

China Shineway Pharmaceutical Group Ltd. is an investment holding company, which engages in the research and development, manufacturing, and trading of Chinese pharmaceutical products. The company is headquartered in Shijiazhuang, Hebei and currently employs 2,867 full-time employees. The company went IPO on 2004-12-02. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The firm operates its business in mainland China and Hong Kong markets.